Vnitr Lek 2022, 68(3):191-194 | DOI: 10.36290/vnl.2022.038

Dyslipidemia and PCSK9 inhibitors - practical focused update of indication and reimbursement criteria

Vladimír Soška
Oddělení klinické biochemie, Fakultní nemocnice u sv. Anny v Brně

PCSK9 inhibitors are modern and effective hypolipidemic drugs for lowering LDL-cholesterol, which belong to the "biological therapy". Their prescription is limited to specialized centers and to the fulfillment of other conditions set by SÚKL. This article lists the current valid criteria under which they can be indicated for reimbursement from public health insurance, and comments conditions and limitations in terms of the possibility of their fulfillment in clinical practice.

Keywords: familial hypercholesterolemia, cardiovascular diseases, LDL‑cholesterol, PCSK9-inhibitors.

Published: April 26, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V. Dyslipidemia and PCSK9 inhibitors - practical focused update of indication and reimbursement criteria. Vnitr Lek. 2022;68(3):191-194. doi: 10.36290/vnl.2022.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. Am J Cardiol. 1995;75:1130-1134.
    2. Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337. Go to original source... Go to PubMed...
    3. Ceska R, Taborsky M, Vrablik M. Consensus statement of professional associations on prescribing of PCSK9-inhibitors. Vnitr Lek.64:1131-1136. Go to original source...
    4. Ling H, Burns TL, Hilleman DE. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low‑density lipoprotein cholesterol. Cardiovasc Ther. 2014;32:82-88. Go to original source... Go to PubMed...
    5. Navarese EP, Kolodziejczak M, Schulze V et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta‑analysis. Ann Intern Med. 2015;163:40-51. Go to original source... Go to PubMed...
    6. Schwartz GG, Bessac L, Berdan LG et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long‑term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168:682-689. Go to original source... Go to PubMed...
    7. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376:1713-1722. Go to original source... Go to PubMed...
    8. Praluent. https://www.sukl.cz Rozhodnutí F‑CAU-003-02R/31. 8. 2018, 20. 08. 2020.
    9. Repatha. https://www.sukl.cz/ Rozhodnutí F‑CAU-003-02R/31. 8. 2018, 7. 1. 2021.
    10. SÚKL. Rozhodnutí o změně podmínek úhrady léčivého přípravku Repatha 140MG INJ SOL 2x1ML, správní řízení sp. zn. SUKLS29290/2019, č. jedln. sukl4530/2021 ze dne 7. 1. 2021.
    11. SÚKL. Rozhodnutí o změně podmínek úhrady léčivého přípravku Praluent 75 mg, F‑CAU-003-02R/31. 08. 2018, Sp. zn. SUKLS85942/2019, č. jedn. sukl209748/2020, ze dne 20. 8. 2020

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.